Physician profile
J David Moore
NPI 1497767792
$4,260.06
in general payments reported to CMS, 2019-2025
16 companies · $405 in 2025
The $405 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,082 · 2020: $498 · 2021: $425 · 2022: $527 · 2023: $689 · 2024: $634 · 2025: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,728.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,728.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $553.28 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $529.71 | 2019-2025 | Trintellix |
| Abbvie INC. | $457.71 | 2021-2024 | |
| Axsome Therapeutics, INC. | $451.40 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $435.09 | 2019-2024 | Rexulti |
| Allergan, INC. | $382.44 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $326.58 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $291.87 | 2021-2023 | |
| Supernus Pharmaceuticals, INC. | $264.93 | 2023-2024 | Qelbree, Qelbree |
| Stryker Corporation | $224.78 | 2019 | |
| Idorsia Pharmaceuticals US INC | $183.01 | 2022-2025 | Quviviq, Quviviq |
| Eisai INC. | $47.60 | 2021 | |
| Shire North American Group INC | $40.40 | 2019 | |
| Corium, LLC | $38.21 | 2022-2023 | Azstarys |
| Lundbeck LLC | $16.76 | 2024 | Rexulti |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $16.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw J David Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.